Clinical TrialMay 21, 2026, 05:32 PM
Zentalis: Azenosertib + Paclitaxel Shows 39% ORR in Ovarian Cancer
AI Summary
Zentalis Pharmaceuticals announced that data from Part 1 of its Phase 1b MUIR trial for azenosertib in combination with paclitaxel for platinum-resistant ovarian cancer (PROC) will be presented at the 2026 ASCO Annual Meeting. The trial showed encouraging clinical activity in an all-comer PROC population, with an Overall Response Rate (ORR) of 39.1% and a median Progression-Free Survival (PFS) of 7.3 months. The combination demonstrated a manageable safety profile with a low rate of high-grade adverse events, suggesting broad potential for azenosertib.
Key Highlights
- Overall Response Rate (ORR) was 39.1% (95% CI: 25.1–54.6) in all-comer PROC patients (n=46).
- Median Progression-Free Survival (PFS) was 7.3 months (95% CI: 3.7–7.5) in all-comer PROC patients.
- Clinical Benefit Rate (CBR) was 58.7% (95% CI: 42.2–73.0) in all-comer PROC patients.
- At the 250 mg intermittent dose (n=12), ORR was 50.0% (95% CI: 21.1–78.9), including one complete response.
- Median Duration of Response (DOR) was 5.6 months (95% CI: 5.6–9.2) in all-comer patients.
- Most frequent Grade ">=3" TRAEs were neutropenia (30.4%) and anemia (19.6%).
- Clinical activity was comparable in Cyclin E1-positive (ORR: 41.4%) and Cyclin E1-negative (ORR: 35.7%) patients.
Price Impact
More from ZNTL